Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 17, 2026.

Biomarkers of Cellular Senescence and Skin Aging

Audrey S. Wang, Oliver Dreesen

Frontiers in Genetics · 2018 · Review · CC BY

doi:10.3389/fgene.2018.00247

Abstract

Cellular senescence is an irreversible growth arrest that occurs as a result of different damaging stimuli, including DNA damage, telomere shortening and dysfunction or oncogenic stress. Senescent cells exert a pleotropic effect on development, tissue aging and regeneration, inflammation, wound healing and tumor suppression. Strategies to remove senescent cells from aging tissues or preneoplastic lesions can delay tissue dysfunction and lead to increased healthspan. However, a significant hurdle in the aging field has been the identification of a universal biomarker that facilitates the unequivocal detection and quantification of senescent cell types in vitro and in vivo. Mammalian skin is the largest organ of the human body and consists of different cell types and compartments. Skin provides a physical barrier against harmful microbes, toxins and protects us from ultraviolet radiation. Increasing evidence suggests that senescent cells accumulate in chronologically- and photoaged human skin; and may contribute to age-related skin changes and pathologies. Here, we highlight current biomarkers to detect senescent cells and review their utility in the context of skin aging. In particular, we discuss the efficacy of biomarkers to detect senescence within different skin compartments and cell types, and how they may contribute to myriad manifestations of skin aging and age-related skin pathologies.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Cellular Senescence and Organismal Aging

Aging is the result of a gradual functional decline at the cellular, and ultimately, organismal level, resulting in the development of myriad chronic illnesses including heart disease, stroke and diabetes. On a cellular level, aging was first described by, who demonstrated that somatic mammalian cells have a finite propensity for cell division, after which they enter an irreversible growth arrest termed cellular senescence. Senescent cells are characterized by their inability to proliferate, resistance to apoptosis, and secretion of factors that promote inflammation and tissue deterioration. The molecular basis underlying Hayflick’s observations came to light only decades later. In the early 1970s, Watson and Olovnikov proposed that during semi-conservative DNA replication of linear chromosomes, the removal of the terminal RNA primer, required to initiate lagging strand synthesis, would result in a gap that can no longer be filled by conventional DNA polymerases. As a result of this “end replication problem", chromosome terminal sequences, termed telomeres shorten during each replication cycle. Critically shortened telomeres trigger a persistent activation of DNA damage response (DDR) pathways, thereby resulting in cellular senescence. It is now clear that several types of cellular stressors can trigger senescence. These include telomere shortening and dysfunction, inadvertent activation of oncogenes, termed oncogene-induced senescence (OIS), changes in chromatin structure and epigenetic stress, oxidative stress, mitochondrial dysfunction, or persistent activation of DNA damage checkpoints. There is increasing evidence suggesting that senescent cells accumulate in aging tissues and organs, thereby impairing physiological processes, including regeneration, and contributing to organismal aging.

Senescence Biomarkers

The identification of unique markers that unequivocally detect and quantify senescent cells, particularly in vivo, remains challenging. Senescent cells display an enlarged and flattened cell shape, and elevated senescence-associated β-galactosidase (SA-β-gal) activity, which remains the gold standard to identify senescent cells in culture and tissue samples. However, this assay requires active enzymatic SA-β-gal activity, which is retained in fresh tissue samples but often lost in fixed or cryopreserved tissues. In addition, non-specific SA-β-gal activity can be detected in early passage adult melanocytes proliferating in culture, in hair follicles, sebaceous glands, and eccrine glands and ducts in both young and old human skin, as well as in proliferating surface luminal cells of the duodenum. Importantly, it remains difficult to multiplex the conventional detection method for SA-β-gal with other senescence-associated or cell-type specific markers, hence limiting the ability to identify senescent cell types or populations within a complex tissue or organ. Toward this goal, a modified flow cytometry-based method of multiplexing SA-β-gal with other senescence markers has been reported. However, such multiplexing strategies involving SA-β-gal in tissue biopsies in situ remains laborious. Despite being a hallmark of senescent cells, SA-β-gal activity does not play a mechanistic role in triggering senescence: cells from patients with autosomal recessive G(M1)-gangliosidosis lack lysosomal β-gal activity, but retain their ability to senesce.

As senescent cells are terminally growth arrested, cell cycle regulators such as p16INK4a, p21CIP1 and p53 are commonly employed to detect senescent cells. p16INK4a, p21CIP1 and p53 were simultaneously upregulated in human skin fibroblasts post-ultraviolet (UV) radiation. p16INK4a plays a key role in cell cycle control upstream of the retinoblastoma tumor suppressor protein, and p16INK4a-positive senescent cells accumulate in an age-dependent manner in multiple tissues including the skin. p16INK4a-positive cells accumulate in preneoplastic lesions, including melanocyte-rich benign human nevi, caused by activating mutations in N-RAS or its downstream target BRAF. Considering the role of p16INK4a in mediating senescence, it is not surprising that this locus is frequently mutated in a variety of human cancers, including skin epithelial tumors.

Although less well understood, senescence is also characterized by widespread chromatin remodeling. Normal cellular aging is associated with global heterochromatin loss, characterized by markers H3K9me3 and H3K27me3. In agreement with these findings, cells from patients with the accelerated aging syndrome Hutchinson–Gilford progeria syndrome (HGPS) exhibit a profound loss of heterochromatin. Predominantly during OIS in vitro, heterochromatin is redistributed into 30–50 punctate DNA-dense senescence-associated heterochromatin foci (SAHF). SAHF are silent domains that co-localize with H3K9me3 and heterochromatin protein 1 (HP1) and may lock cells in a senescent state by transcriptionally repressing genes involved in cell proliferation. In contrast, SAHF formation was not observed in HGPS patient cells or preneoplastic lesions that express other senescence markers. Long-term monitoring of senescent cells in vitro revealed progressive proteolysis of Histones 3 and 4 without DNA loss. Reduced histone content was also observed in nevus melanocytes, as compared to neighboring non-senescent melanocytes and keratinocytes in vivo. These studies confirm the dramatic structural changes of chromatin in senescent cells. In addition, the same authors also noted the presence of cytoplasmic chromatin fragments (CCFs) in ∼20% of cells undergoing replicative senescence (RS) or OIS in vitro. CCFs were positive for H3K9me3 and γ-H2A-X, but negative for 53BP1 and lamin A/C, and targeted for degradation by autophagy. The accumulation of such chromatin fragments within the cytoplasm suggests that the integrity of the nuclear envelope becomes compromised in senescent cells.

Indeed, the nuclear lamina, a proteinaceous network that lies beneath the inner nuclear membrane, undergoes dramatic remodeling during cellular senescence. Lamin B1, an intermediate filament protein expressed in all somatic cells, is downregulated in cells undergoing RS, OIS and UV-induced senescence in vitro. Lamin B1 levels also decline during chronological aging of human skin in vivo, in senescent melanocytes within human nevi, in UV-exposed mouse skin epidermis, irradiated mouse liver and in kidneys of a premature aging mouse model. Importantly, by co-staining with cell-type specific markers, lamin B1 staining facilitated the identification and quantification of senescent melanocytes within nevi as compared to neighboring keratinocytes within the epidermis. Similarly, co-staining lamin B1 with a keratinocyte differentiation marker followed by single cell analysis enabled us to quantify the accumulation and clearance of senescent cells in different epidermal compartments after UV exposure and upon regeneration, respectively. In addition to lamin B1, the inner nuclear membrane protein lamin B receptor (LBR) and the lamina-associated polypeptide-α (LAP2α) are also downregulated in senescent cells. However, LBR levels vary within the different epidermal layers in mouse skin, indicating that its expression may be altered during keratinocyte differentiation. Hence, this may limit the usage of LBR as an adequate senescence marker in human skin. Moreover, loss of LAP2α is not specific to senescent cells and also occurs in quiescent cells. Thus, co-staining of lamin B1 and LAP2α distinguishes senescent from quiescent cells. The mechanism of senescence-induced lamin B1 downregulation has been elucidated in detail by several groups. LMNB1 transcription is decreased and LMNB1 mRNA is destabilized, possibly via targeted degradation by miR-23a. Additionally, lamin B1 protein is shuttled to the cytoplasm and degraded via autophagy. It should be noted that LMNB1 mRNA levels alone are not a reliable indicator of senescence. For instance, LMNB1 mRNA levels decrease in contact-inhibited quiescent fibroblasts, whereas lamin B1 protein levels remain stable as cells do not turn over. Taken together, although the mechanistic role of lamin B1 during cellular senescence is not fully understood, loss of lamin B1 is emerging as a potentially important biomarker to identify and quantify senescent cells in vitro and in vivo.

Concomitant with senescence-associated loss in chromatin organization, overall DNA methylation and expression of the DNA methyl-transferase DNMT1 decrease during cellular aging. These altered DNA methylation signatures can distinguish cells based on their developmental potential and may be used to predict chronological and biological age. Such distinct methylation patterns are also associated with chronologically aged and photoaged skin.

Persistent DNA damage is a critical trigger of cellular senescence and can be identified by the presence of γ-H2A-X and 53BP1 foci and activated ataxia-telangiectasia mutated (ATM) kinase. However, while DNA damage per se, is not a marker for cellular senescence, the occurrence of telomere-associated DNA damage foci (TAF) has been used to detect senescent cells and quantify tissue aging. Replicative senescent baboon skin fibroblasts and skin biopsies from aged baboons displayed high incidence of TAF as indicated by co-localization of 53BP1 and γ-H2A-X on telomeric DNA. In agreement with these findings, shortened telomeres have been detected in skin from aged individuals, in sun-exposed skin and premalignant skin lesions including actinic keratosis (AK). Other age-related genomic changes occur in mitochondrial DNA (mtDNA): age-dependent increase of mtDNA mutations and a common 4977 bp mtDNA deletion have been reported in several human tissues and cell types, as well as in photoaged human skin. Lastly, a histone variant H2A.J accumulates in an age-dependent manner in mouse and human skin, and in irradiated mouse skin. Both H2A.J and p16INK4a levels were elevated in carcinogen-induced preneoplastic lesions but decreased in more advanced papillomas in mouse skin. H2A.J upregulation promotes expression of inflammatory genes, further exacerbating the senescence-induced hyperinflammation.

For long, senescent cells were considered passive bystanders that ceased to proliferate. Research in the past decade revealed that senescence can dramatically change cell function. For instance, senescent cells modulate their environment by secreting inflammatory cytokines, chemokines, matrix metalloproteinases (MMPs) and growth factors, collectively known as the senescence-associated secretory phenotype (SASP) or senescence-messaging secretome (SMS). As such, the presence of MMPs (e.g., MMP3 and MMP9), chemokines (e.g., CXCR2), cytokines (e.g., IL-6 and IL-8) and insulin-like growth factor binding protein 7 (IGFBP7) has been used as markers for senescent dermal fibroblasts and melanocytes in vitro. In vivo, elevated IL-6 has been detected in nevi melanocytes while MMPs are detected in chronologically aged and photoaged skin, and are responsible for breakdown of the extracellular matrix (ECM). In addition, the plasminogen activator inhibitor type 1 (PAI-1), an inhibitor of serine proteases, is elevated in dermal fibroblasts derived from patients with the premature aging syndromes HGPS and Werner, chronologically aged donors, and in tissues of premature aging BubR1 mutant mice. PAI-1 plays a role in triggering senescence downstream of p53 and is both a mediator and marker of senescence. Interestingly, most studies focused on fibroblasts in vitro and it remains to be determined whether the secretome of other senescent cell types differs – and how this may affect the function of neighboring cells. It is noteworthy that expression of p53 or p16INK4a alone may not be sufficient to trigger a SASP as a persistent DDR is mandatory.

High mobility group box-1 (HMGB1) belongs to the family of alarmins, which is an inflammatory mediator important in tissue damage signaling. In senescent cells, HMGB1 translocates from the nucleus to the cytoplasm and extracellular space, facilitating the release of SASP factors including IL-1β, IL-6 and MMP3. UVB-exposure stimulated the release of HMGB1, IL-1 and IL-6 in human keratinocytes in vitro, and reduced nuclear Hmgb1 expression in mouse skin epidermis in vivo. Although HMGB1 is used as a marker to detect senescent cells in various contexts, its utility to detect senescent cells in human skin remains to be investigated.

Taken together, various senescence markers are currently being used individually and in combination, in different biological contexts in vitro and in vivo (Figure 1 and Table 1). Nevertheless, further characterization of current markers and the identification of additional markers are indispensable to reliably detect and quantify senescent cells in vitro and in vivo. In particular, it is essential to develop better methods to multiplex senescence markers with other cell-type specific markers to identify and quantify senescent cell types in multi-compartment organs such as the skin and its appendages including sebaceous glands and hair follicles. Here, we will focus on what is known about the accumulation of senescent cells in skin, how they may affect skin function and contribute to age-related skin pathologies.

Skin Aging

Skin is the largest organ of the human body: it provides a barrier against harmful organisms and substances, protects against UV radiation and regulates water loss and body temperature. The skin is a complex organ, consisting of several compartments with different functions. The outermost epidermis is stratified into four sublayers (basal, spinous, granular and cornified layer) with keratinocytes being the predominant cell type. Pigment-producing melanocytes reside within the basal layer of the epidermis, determine skin color and possess photo-protecting properties (Figure 1). The dermal-epidermal junction (DEJ) connects the epidermis to the underlying dermis, which harbors dermal fibroblasts and appendages such as hair follicles, sebaceous glands, and sweat glands.

Skin aging is a multi-factorial process that affects nearly every aspect of its biology and function; it is driven by both intrinsic (e.g., time, genetic factors, hormones) and extrinsic (e.g., UV exposure, pollution) factors. Characteristics of intrinsic or chronological aging include visible signs such as thin and dry skin, fine wrinkles, decreased elasticity, aberrant pigmentation, hair graying and hair loss. Epidermal thinning is, in part, caused by decreased proliferation and renewal capacity of basal keratinocytes and reduced epidermal stem cell number. Besides the epidermis, both the DEJ and dermis also become thinner. Fibroblasts residing within the dermis generate an ECM that provides the skin with structural integrity and elasticity. During aging, the ECM undergoes structural alterations and degradation (Figure 1), thought to result in dermal thinning, increased wrinkling and loss of elasticity. Although the number of senescent cells increases during chronological aging of human skin, a more detailed characterization as to which cell types or skin compartment undergoes senescence is necessary.

UV and Skin Aging

In addition to chronological aging, extrinsic factors including exposure to sunlight, pollutants and cigarette smoke can accelerate skin aging. While most UVC is blocked by the ozone layer, UVA and UVB rays reach the earth’s surface and contribute to skin aging and cancer development. UVA is a weak mutagen, yet penetrates into the dermis contributing to oxidative stress and tissue inflammation. UVB is more mutagenic as it directly interacts with DNA to generate dipyrimidine photoproducts, resulting in DNA damage during DNA replication. Acute UV radiation results in sunburns, aberrant pigmentation and immune suppression, whilst chronic exposure is associated with premature skin aging and a predisposition to develop malignancies. Sun-exposed skin appears thick and rough, marked with coarse wrinkles, visible appearance of blood vessels under the skin surface (telangiectasia) and aberrant pigmentation. A key histological hallmark of photodamaged skin is the accumulation of amorphous elastic fibers (solar elastosis), accompanied by fragmented and disorganized collagen in the dermis. Solar elastosis may be a consequence of impaired elastic and fibrillin production, elevated breakdown by MMPs secreted by senescent cells, or a direct consequence of UV exposure. In vitro, UVB-exposed skin cell types (fibroblasts, keratinocytes) exhibit DNA damage, cell cycle arrest and express senescence biomarkers such as increased SA-β-gal activity, p16INK4a, p21CIP1, p53 activation and lamin B1 downregulation. In vivo, chronic low dose exposure to UVB resulted in accumulation of DNA damage and lamin B1-low senescent cells within the mouse epidermis, but not the dermis, a reduction in stem cell numbers in the hair follicle, and p21CIP1 accumulation in epidermis and hair follicle stem cell region.

Although the number of melanocytes in our skin decreases and skin color in sun-protected areas lightens with age, aberrant pigmentation (hyper- and hypopigmentation; i.e., sun spots and freckles) occurs at chronically sun-exposed body parts. Interestingly, in a 3D organotypic skin model comprised of keratinocytes, melanocytes and fibroblasts, the presence of aged fibroblasts resulted in increased melanogenic gene transcription, increased epidermal melanin and hyperpigmentation. Diverse pigmentary changes occur in aged skin and future studies will investigate whether senescent cell types accumulate at these lesions and how they may affect pigmentation. We anticipate that multiplexing senescence markers with cell-type specific markers will shed light as to how chronological aging and/or UV exposure modulate the complex interplay between pigment-producing melanocytes and their neighboring epidermal keratinocytes and dermal fibroblasts.

Pollution and Skin Aging

More recently, it has been shown that air pollution contributes to various aspects of skin aging. Residents living near highly polluted areas and exposed to high levels of traffic-related particles and nitrogen dioxide developed pigmentary changes and increased coarse wrinkles. Similarly, exposure to tobacco smoke accelerates skin aging, resulting in increased wrinkling, elastosis, telangiectasia and laxity in the skin. Application of tobacco extracts to skin and oral fibroblasts in vitro triggered several hallmarks of senescence including premature cell cycle arrest, oxidative DNA damage, secretion of inflammatory cytokines and MMPs, and downregulation of cell junction proteins E-cadherin and ZO-1. The ability to detect and quantify senescent cells in aged skin is indispensable to further elucidate how pollution may accelerate senescence and how this in turn alters skin appearance and function.

Whilst aging results in dry, itchy and more irritable skin, the underlying cause is likely multifactorial and involves changes in skin barrier function, androgen levels and sebaceous gland function. Sebaceous glands contribute to skin oiliness and moisture by secreting a complex mix of lipids called sebum. While the number of sebaceous glands does not change during aging, its activity drastically decreases in postmenopausal females and males over 80 years old. Somewhat counterintuitive, contrasting its declining function and sebum production, the size of the sebaceous gland increases with age. Chronic UV exposure has also been implicated in sebaceous hyperplasia and carcinoma. The specific involvement of cellular senescence in aging of the pigmentary units and sebaceous glands remains to be explored in greater detail.

Genetic Diseases and Skin Aging

Multiple genetic syndromes that result in persistent DNA damage or telomere dysfunction (telomeropathies) and cellular senescence, predispose the skin to accelerated aging and/or carcinogenesis. HGPS is a rare early-onset premature aging syndrome caused by a mutation in lamin A, resulting in a truncated mutant protein termed progerin. HGPS patients exhibit signs of accelerated aging at 12–18 months after birth and die in their mid-teens as a result of cardiovascular complications. Early clinical signs include alopecia, sclerotic skin, loss of subcutaneous fat and aberrant skin pigmentation. At the cellular level, progerin expression results in atypical nuclear architecture, heterochromatin loss, DNA damage and premature senescence. The primary driver mechanisms of these complex cellular phenotypes remain unclear. Progerin sequestration of NRF2, a major factor in a cell’s response to oxidative stress, has been suggested to play a role in progerin-dependent heterochromatin loss and DNA damage. Other studies linked progerin-induced DNA damage to replication defects and telomere dysfunction.

Mandibuloacral dysplasia (MAD) and restrictive dermopathy (RD) are also caused by nuclear lamina aberrations. Similar to HGPS, MAD is caused by a lamin A mutation and patients exhibit growth retardation, skeletal abnormalities, skin atrophy and hyperpigmentation. RD is a rare neonatal lethal disease in which newborns exhibit intrauterine growth retardation, tight, erosive skin with hyperkeratosis, and sparse eyebrows and hair. RD is caused by loss of ZMPSTE24, a zinc metalloproteinase critical for the correct processing of lamin A. While RD does not reflect skin aging phenotypes per se, the occurrence of these skin-specific laminopathies highlights the importance of nuclear lamina functions in the development and homeostasis of skin and hair.

Werner syndrome (WS), also referred to as adult-onset progeria, is regarded as a milder form of progeria. WS patients start to exhibit clinical features including hair loss and graying, scleroderma-like skin, ulcers and osteoporosis in their 30’s and die in their 50’s due to myocardial infarction and cancer. WS has been linked to mutations in WRN, a member of the RecQ helicase family that lead to defects in DNA replication, repair, and premature cellular senescence. Loss of function mutations in WRN result in defective telomere lagging strand synthesis, telomere loss and genomic instability.

Bloom syndrome is another disorder caused by loss of function mutations in the RecQ DNA helicase and affects DNA replication and repair. Its clinical symptoms include the development of skin rash in sun-exposed areas, accelerated skin aging, alopecia, poikiloderma (irregular pigmentation, telangiectasia, and atrophy) and a predisposition to cancer.

Xeroderma pigmentosum (XP) is a rare autosomal recessive syndrome characterized by extreme sensitivity to sunlight, resulting in sunburn, aberrant pigmentation, dry skin, premature skin aging, and increased risk to develop skin malignancies, including squamous cell carcinoma (SCC), basal cell carcinoma (BCC) and melanoma. The median age of death for XP patients is 29–32 years and most frequently caused by metastatic skin cancers and neurodegeneration. The etiology of XP is characterized by defects in nucleotide excision repair (NER), a key pathway required to repair UVB-induced dipyrimidine photoproducts. Defects in NER lead to the accumulation of DNA damage, genomic instability, impaired cell growth, premature senescence and/or cell death. Similarly, two other disorders caused by NER defects are Cockayne syndrome and trichothiodystrophy (TTD); both diseases are characterized by premature aging, neurological abnormalities and skin photosensitivity. Additionally, TTD patients display rough skin and brittle hair.

Mutations in ATM, an important molecule involved in activating checkpoint signaling in response to DNA double strand breaks, cause Ataxia-telangiectasia, another rare early-onset neurodegenerative disease in which patients display skin abnormalities including vitiligo, hair graying and telangiectasia in sun-exposed skin.

Dyskeratosis congenita (DKC) is multi-systemic premature aging syndrome resulting in some skin defects. Initial clinical features appear during childhood and include abnormal skin pigmentation and nail dystrophy. During the second and third decade, patients develop bone marrow failure, ultimately resulting in their death. In addition, some patients exhibit an increased risk to develop premalignant and malignant lesions, including AK and SCC. DKC is caused by mutations in various components of telomerase (TCAP1, DKC1, TERC, TERT, NHP2, NOP10) or shelterin (TINF2), a protein complex involved in telomerase recruitment and telomere protection. These mutations result in impaired telomere maintenance, presumably in adult stem cell compartments, and premature telomere shortening.

A common feature of the abovementioned genetic syndromes is the accumulation of persistent DNA damage, either by impaired DNA replication, repair, or signaling, as well as by DNA damage at unrepairable loci such as telomeres, resulting in premature cellular senescence and accelerated skin aging. These phenotypes can be recapitulated in patient-derived fibroblasts, cell- or iPSC-based disease models and mouse models. However, the rarity of these genetic diseases coupled with limited access to tissue biopsies have hampered efforts to test whether senescent cells accumulate within patient tissues in vivo. How are these accelerated aging syndromes relevant to normal aging? During chronological aging, at least the accumulation of genomic alterations correlates with the onset of age-related phenotypes and diseases. Furthermore, an increase susceptibility to DNA damage and decline in DNA repair capacity have also been described in aging skin. Chronological aging can be accelerated by extrinsic factors that result in DNA damage, including UV radiation, particles from traffic pollution and cigarette smoke. In conclusion, increased DNA damage, impaired repair or signaling play a key conserved feature of premature aging syndromes and normal aging.

Role of Cellular Senescence in Wounds and Cancers

Aging results in a progressive decline of skin function, leading to fragility, impaired barrier function, increased susceptibility to physical insults, infection, accumulation of age-related pathologies such as impaired wound healing and an increased risk of cancer.

Skin wound healing occurs in four stages: hemostasis, inflammation, proliferation and remodeling. Wound closure takes place during the proliferation phase and depends on the formation of granulation tissue and the generation of contractile myofibroblasts. A ground breaking study by demonstrated that senescent cells transiently accumulate during the proliferative stage and secrete platelet-derived growth factor AA (PDGF-AA) to induce myofibroblasts differentiation and maturation, essential for wound closure. Elimination of senescent cells reduced the number of myofibroblasts, delayed wound closure and increased fibrosis, all of which could be prevented by ectopic administration of PDGF-AA. Similarly, senescent cells prevent fibrosis during liver regeneration. These results demonstrate that senescent cells play an important role in tissue repair via cell-autonomous mechanisms: in the skin through the secretion of PDGF-AA; in the regenerating liver by secreting Mmp9, Mmp13 and IL-6. Thus, senescent cells may limit tissue regeneration in order to protect against unrestricted cell proliferation. On the flip side, a prolonged presence of senescent cells in the elderly prevents re-epithelialization and wound closure resulting in chronic wounds. Taken together, cellular senescence plays a complex role during normal wound healing as well as in chronic wounds.

Senescence and Skin Cancer

Cellular senescence is a double-edged sword: on the one hand, the accumulation of senescent cells may contribute to various age-related complications; on the other hand, RS and OIS suppress uncontrolled proliferation of cells that are at risk for preneoplastic transformation, thereby limiting tumorigenesis. As a result, cells from premalignant clinical specimens of breast, colon, lung and bladder tumors exhibited persistent DNA damage checkpoint activation and expressed some senescence markers. Besides promoting non-cell-autonomous growth inhibition, the production of SASP is also critical for the recruitment of immune cells that create an anti-tumorigenic microenvironment important for the clearance of senescent cells.

In the skin, the vast majority of benign nevi are caused either by activating mutations in N-RAS or BRAF, and are unlikely to progress toward melanoma. Melanocytes within these preneoplastic lesions are positive for multiple senescence markers, including SA-β-gal, p16INK4a and loss of lamin B1, which are absent in more advanced melanoma. Kras mutant mice also expressed increased senescence markers in premalignant lung and pancreatic adenomas, and in chemically induced skin papillomas.

Skin cancer represents the most common human cancer type and its incidence increases with age and UV exposure. Long-term exposure to sunlight results in persistent DNA damage, increased cellular senescence and formation of premalignant lesions such as AK. AK affects approximately 60% of individuals above the age of 40 with a history of sun exposure. If left untreated, a percentage of AK lesions will progress toward invasive SCCs. Clinically, 97% of SCCs are contiguous with AK yet the risk of progression or regression remains difficult to assess. Although cells within AK lesions exhibit genomic instability and telomere shortening, it is unclear whether senescent cells accumulate within AK lesions. As senescent cells generally accumulate in premalignant, but not malignant lesions, the identification and quantification of senescent cells within AK lesions may serve as a valuable tool to diagnose and distinguish AK from SCC and predict the course of disease progression.

Senescent Cells: Therapeutic Opportunities for Cancer and Aging

Numerous studies have aimed at preventing the accumulation of senescent cells within aging tissues. However, strategies that involve blocking p16INK4a and p53, or activating telomerase to extend the proliferative capacity of cells inevitably lead to an increased cancer risk. Thus, a safer approach might be to either selectively eliminate senescent cells from tissues or modulate their function (particularly the SASP). The use of a progeroid mouse model expressing a mutated form of the mitotic checkpoint BubR1 has proven instrumental in demonstrating that p16INK4a-positive senescent cells drive age-related pathologies, and that selective elimination of these cells can prevent or delay age-related tissue deterioration. Similarly, clearance of p16INK4a-positive cells in normal-aging mice extended their median lifespan, delayed tumorigenesis, improved healthspan indices including heart and kidney function, and delayed age-related decline in exploratory behavior. Multiple recent studies confirmed that clearing senescent cells improved tissue function in various age-related pathologies including degenerative joint disease, hepatic fat accumulation and liver chemotoxicity. These studies established senescent cells as potential therapeutic targets in the treatment of aging and age-related diseases. As a result, compounds that selectively eliminate senescent cells (senolytics) are under investigation to treat and prevent various age-related diseases. While several molecular pathways that trigger senescence are under consideration for the development of senolytics, the majority are directed at the pathways that confer apoptosis-resistance in senescent cells (in particular the anti-apoptotic BCL protein family). However, few studies have probed how treatment with senolytics may affect skin function and homeostasis. In one study involving a skin-specific keratin 5-driven p14ARF transgenic mouse model, senescent epidermal cells were efficiently eliminated upon delivery of ABT-737, a BCL-specific senolytic compound. Although elimination of senescent cells from the epidermis led to increased proliferation within hair follicles, the underlying mechanism or other consequences on skin function were not investigated. Thus, it remains to be determined whether senolytics offer novel therapeutic approaches to treat chronic wounds, skin inflammation, age-related pigmentation disorders and ECM breakdown, or whether their clearance would impair wound healing or other skin functions in younger individuals.

A prerequisite for any such studies is a better understanding as to which skin compartment or cell type becomes senescent in the myriad age-related skin pathologies. Multiplexing senescence biomarkers with cell-type specific markers will pave the way to address this question. In addition, it is important to better understand how senescence affects or modulates the function of various skin cell types. To date, most SASP studies have focused on dermal fibroblasts and little is known about the SASP of other skin resident cell types, including melanocytes, keratinocytes or cell types from skin appendages, such as sebocytes. This is particularly relevant in skin as the interplay between these different cell types is essential to regulate skin functions including pigmentation, barrier function, sebum production, wound healing and cancer progression.

Conclusion

The recognition of the role of cellular senescence in tissue aging has progressed tremendously in the past decade and this is in part attributed to better characterization of senescence biomarkers which allows qualitative and quantitative detection of senescent cells in vitro and in situ. Recent studies provided evidence that senescent cells accumulate in aged skin and may be driving the functional deterioration that characterizes aging skin and age-related skin diseases. Improved methodologies to detect senescent cells and a better understanding how senescence affects cellular function will enable us to determine how they contribute to various age-related skin changes and pathologies, including impaired wound healing and tumorigenesis. Moreover, the careful evaluation of senolytics in animal models and 3D reconstructed skin organotypics will facilitate the successful translation of senolytics as a therapeutic intervention for skin aging. The accessibility of human skin offers advantages to test these hypotheses.

Author Contributions

OD and AW wrote the manuscript and prepared the figures.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 214

  1. 1.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  2. 2.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  3. 3.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  4. 4.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  5. 5.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  6. 6.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  7. 7.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  8. 8.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  9. 9.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  29. 29.
  30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  41. 41.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  42. 42.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  43. 43.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  44. 44.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  46. 46.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  47. 47.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  49. 49.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  50. 50.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  51. 51.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  52. 52.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  53. 53.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  54. 54.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  55. 55.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  56. 56.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  57. 57.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  58. 58.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  59. 59.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  60. 60.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  61. 61.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  62. 62.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  63. 63.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  64. 64.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  65. 65.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  66. 66.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  67. 67.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  68. 68.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  69. 69.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  70. 70.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  71. 71.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  72. 72.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  73. 73.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  74. 74.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  75. 75.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  76. 76.
  77. 77.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  78. 78.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  79. 79.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  80. 80.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  81. 81.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  82. 82.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  83. 83.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  84. 84.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  85. 85.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  86. 86.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  87. 87.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  88. 88.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  89. 89.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  90. 90.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  91. 91.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  92. 92.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  93. 93.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  94. 94.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  95. 95.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  96. 96.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  97. 97.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  98. 98.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  99. 99.
  100. 100.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  101. 101.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  102. 102.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  103. 103.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  104. 104.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  105. 105.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  106. 106.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  107. 107.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  108. 108.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  109. 109.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  110. 110.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  111. 111.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  112. 112.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  113. 113.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  114. 114.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  115. 115.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  116. 116.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  117. 117.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  118. 118.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  119. 119.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  120. 120.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  121. 121.
  122. 122.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  123. 123.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  124. 124.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  125. 125.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  126. 126.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  127. 127.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  128. 128.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  129. 129.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  130. 130.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  131. 131.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  132. 132.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  133. 133.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  134. 134.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  135. 135.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  136. 136.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  137. 137.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  138. 138.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  139. 139.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  140. 140.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  141. 141.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  142. 142.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  143. 143.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  144. 144.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  145. 145.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  146. 146.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  147. 147.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  148. 148.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  149. 149.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  150. 150.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  151. 151.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  152. 152.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  153. 153.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  154. 154.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  155. 155.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  156. 156.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  157. 157.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  158. 158.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  159. 159.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  160. 160.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  161. 161.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  162. 162.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  163. 163.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  164. 164.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  165. 165.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  166. 166.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  167. 167.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  168. 168.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  169. 169.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  170. 170.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  171. 171.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  172. 172.
  173. 173.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  174. 174.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  175. 175.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  176. 176.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  177. 177.
  178. 178.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  179. 179.
  180. 180.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  181. 181.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  182. 182.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  183. 183.
  184. 184.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  185. 185.
  186. 186.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  187. 187.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  188. 188.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  189. 189.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  190. 190.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  191. 191.
  192. 192.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  193. 193.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  194. 194.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  195. 195.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  196. 196.
  197. 197.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  198. 198.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  199. 199.
  200. 200.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  201. 201.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  202. 202.
  203. 203.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  204. 204.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  205. 205.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  206. 206.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  207. 207.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  208. 208.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  209. 209.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  210. 210.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  211. 211.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  212. 212.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  213. 213.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

  214. 214.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 11

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.